Back to top

At the Conference on Retroviruses and Opportunistic Infections (CROI 2025), researchers presented results from phase 2 proof-of-concept trials examining two long-acting antiretroviral drugs being developed by ViiV Healthcare, VH-184 and VH-499, and concluded that both formulations are as effective as current antiretroviral medications, raising hopes that these drugs could eventually be added to the long-acting antiretroviral therapy (ART) toolbox and eventually give people with HIV more options that don’t require a daily pill.

VH-184, a third-generation integrase strand transfer inhibitor (INSTI), was studied for efficacy, safety and tolerability as an oral monotherapy in a phase 2a trial, and was found to be as potent as INSTIs such as dolutegravir, researchers said. 

In this double-blind, placebo-controlled trial, 22 participants, all who had never previously received ART and all with viral loads of at least 3,000 copies/mL, were randomized to receive oral VH-184 at 10, 50, or 300 mg or a placebo on Days 1, 4 and 7. After Day 10, all participants were switched to standard-of-care antiretrovirals. The mean age of participants was 34 years, and most were male (86%) and White (68%), while 14% were Black or African American and 59% identified as Hispanic or Latin American ethnicity. 

Looking at the maximum change in viral load from baseline to Day 10, researchers discovered that VH-184 led to “rapid and highly potent” antiviral activity, resulting in a significant decline in HIV-1 RNA levels, with the 300 mg dose group experiencing a greater decline than the 10 mg or the 50 mg groups. “An exposure-response relationship was established comparable to the maximum effect with other INSTIs,” such as dolutegravir, researchers wrote. No participants developed genotypic or phenotypic resistance to VH-184 by the end of the study period, and the formulation was well tolerated and resulted in no serious adverse events (all adverse events were graded as mild). 

“The findings of this trial support further development of VH-184 as a potential long-acting injectable antiretroviral,” ViiV said in a news release.  The company also plans to investigate long-acting injectable formulations of VH-184 in an ongoing phase 1 study. 

VH-499, an investigational HIV-1 capsid inhibitor, is also being developed by ViiV as a potential long-acting injectable treatment. Currently, only one capsid inhibitor is approved for HIV treatment, lenacapavir (marketed by Gilead as Sunlenca), which is given as a twice-yearly injection. ViiV conducted a phase 2a study to evaluate the safety and effectiveness of oral VH-499 over a 10-day period. Similar to the VH-184 group, participants were mostly male (83%) and white (65%), while 17% were Black or African American and 65% identified as Hispanic or Latin American. The median age was 31 years.

Twenty-three participants, previously untreated adults with HIV with viral loads above 3,000 copies/mL, were enrolled and randomized to receive VH-499 at doses of 25 mg (7 participants), 100 mg (6), or 250 mg (7) or a placebo (3) on days 1 and 6. After the monotherapy period, participants started standard-of-care ART. 

Researchers were looking for the maximum change from baseline in viral load to Day 10 and “demonstrated highly potent antiviral activity in people living with HIV-1, with up to a mean maximum 2.2 log10 c/mL reduction in HIV-1 RNA over 10 days.” VH-499 monotherapy was well tolerated and had a favorable safety profile with no serious adverse events (most adverse events were mild), leading to treatment discontinuations. However, one participant receiving the 25 mg dose developed a resistance mutation associated with capsid inhibitor resistance and was subsequently switched to dolutegravir/lamivudine (brand name Dovato).

The results “support further development of VH-499 as part of a complete long-acting regimen for the treatment of HIV-1,” researchers wrote.